AP-001 (Avenzoar Pharmaceuticals)

N/A

Report date: 2024/11/06 10:38:22
NME

Base Information

Drug NameAP-001 (Avenzoar Pharmaceuticals)
Drug Alias Namemetavert
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase inhibitorsGlycogen synthase kinase-3 beta inhibitors
TargetsHistone deacetylaseGlycogen synthase kinase-3 beta
Therapy Area/IndicationsLung NeoplasmsPancreatic NeoplasmsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAvenzoar Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAvenzoar Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsPancreatic NeoplasmsLiver Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A